- Home
- JMM vs CRVO Comparison
JMM vs CRVO Comparison
Compare JMM & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMM
- CRVO
- Stock Information
- Founded
- JMM 1988
- CRVO 2001
- Country
- JMM United States
- CRVO United States
- Employees
- JMM N/A
- CRVO N/A
- Industry
- JMM Trusts Except Educational Religious and Charitable
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- JMM Finance
- CRVO Health Care
- Exchange
- JMM Nasdaq
- CRVO Nasdaq
- Market Cap
- JMM 58.6M
- CRVO 67.4M
- IPO Year
- JMM N/A
- CRVO N/A
- Fundamental
- Price
- JMM $6.43
- CRVO $6.96
- Analyst Decision
- JMM
- CRVO Strong Buy
- Analyst Count
- JMM 0
- CRVO 7
- Target Price
- JMM N/A
- CRVO $19.33
- AVG Volume (30 Days)
- JMM 16.1K
- CRVO 161.9K
- Earning Date
- JMM 01-01-0001
- CRVO 08-08-2025
- Dividend Yield
- JMM 5.44%
- CRVO N/A
- EPS Growth
- JMM N/A
- CRVO N/A
- EPS
- JMM N/A
- CRVO N/A
- Revenue
- JMM N/A
- CRVO $9,308,215.00
- Revenue This Year
- JMM N/A
- CRVO N/A
- Revenue Next Year
- JMM N/A
- CRVO N/A
- P/E Ratio
- JMM N/A
- CRVO N/A
- Revenue Growth
- JMM N/A
- CRVO 15.14
- 52 Week Low
- JMM $5.29
- CRVO $1.80
- 52 Week High
- JMM $6.10
- CRVO $20.63
- Technical
- Relative Strength Index (RSI)
- JMM 65.15
- CRVO 51.63
- Support Level
- JMM $6.22
- CRVO $5.45
- Resistance Level
- JMM $6.41
- CRVO $7.55
- Average True Range (ATR)
- JMM 0.11
- CRVO 0.59
- MACD
- JMM 0.01
- CRVO 0.14
- Stochastic Oscillator
- JMM 100.00
- CRVO 75.71
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.